INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $21 | -77.4% | 47,902 | -19.9% | 0.00% | -83.3% |
| Q4 2022 | $93 | -100.0% | 59,812 | -54.3% | 0.01% | -42.9% |
| Q3 2022 | $226,000 | +52.7% | 130,829 | +53.0% | 0.02% | +61.5% |
| Q2 2022 | $148,000 | -31.8% | 85,504 | +181.8% | 0.01% | -31.6% |
| Q3 2021 | $217,000 | +102.8% | 30,338 | +163.6% | 0.02% | +137.5% |
| Q1 2021 | $107,000 | -85.6% | 11,511 | -86.3% | 0.01% | -90.0% |
| Q4 2020 | $744,000 | -5.2% | 84,012 | +24.1% | 0.08% | -40.7% |
| Q3 2020 | $785,000 | +792.0% | 67,686 | +155.0% | 0.14% | +1400.0% |
| Q4 2019 | $88,000 | +183.9% | 26,543 | +75.0% | 0.01% | +350.0% |
| Q3 2019 | $31,000 | -55.7% | 15,164 | -36.4% | 0.00% | -50.0% |
| Q2 2019 | $70,000 | -44.0% | 23,850 | -23.8% | 0.00% | -42.9% |
| Q4 2018 | $125,000 | -36.2% | 31,318 | -24.8% | 0.01% | -36.4% |
| Q1 2018 | $196,000 | +83.2% | 41,629 | +60.2% | 0.01% | +83.3% |
| Q4 2017 | $107,000 | -64.7% | 25,990 | -45.6% | 0.01% | -60.0% |
| Q3 2017 | $303,000 | – | 47,803 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |